Prevail Innovative Wealth Advisors Boosts Vertex Pharmaceuticals Stake

The firm purchased 15,200 additional shares of the biotech company in the third quarter.

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Prevail Innovative Wealth Advisors LLC acquired a new stake of 15,200 shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the third quarter, valued at approximately $5.95 million. This investment represents 1.2% of Prevail Innovative Wealth Advisors' portfolio, making Vertex Pharmaceuticals the firm's 18th largest holding.

Why it matters

Vertex Pharmaceuticals is a leading biotech company focused on developing innovative treatments for serious diseases, particularly cystic fibrosis. The firm's increased investment in Vertex signals confidence in the company's growth potential and pipeline of CFTR modulators that have transformed standards of care for many cystic fibrosis patients.

The details

Prevail Innovative Wealth Advisors LLC purchased the 15,200 shares of Vertex Pharmaceuticals during the third quarter. This new stake represents 1.2% of the firm's total holdings, making Vertex Pharmaceuticals its 18th largest position. Several other hedge funds and institutional investors have also recently increased their positions in Vertex, reflecting the company's strong performance and promising drug pipeline.

  • Prevail Innovative Wealth Advisors acquired the 15,200 Vertex Pharmaceuticals shares in the third quarter of 2026.

The players

Prevail Innovative Wealth Advisors LLC

A wealth management firm that recently purchased a new stake in Vertex Pharmaceuticals, making it one of the company's top holdings.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing innovative treatments for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

Prevail Innovative Wealth Advisors' increased investment in Vertex Pharmaceuticals underscores the biotech company's strong position in the market and the confidence institutional investors have in its ability to continue driving innovation and growth in the pharmaceutical industry.